palsonify logo
PALSONIFY logo

This is Megan. Holding on to what matters. Not thinking about her acromegaly

Meet PALSONIFY. A once-daily oral medication for acromegaly.

PALSONIFY is a prescription medicine used to treat adults with acromegaly for whom surgery was not effective or surgery is not an option.

PALSONIFY helps control IGF-1 levels and symptoms so you can be in the moment*

Ready to ask about PALSONIFY? Use this discussion guide to get the conversation going with your healthcare provider.

Discussion guide

PALSONIFY is a prescription medicine used to treat adults with acromegaly for whom surgery was not effective or surgery is not an option.

*PALSONIFY maintained or lowered IGF-1 and reduced the severity of common acromegaly symptoms in most patients in clinical studies.
IGF-1=insulin-like growth factor 1.

Megan, fitness enthusiast,
living with acromegaly

Who is PALSONIFY for?

PALSONIFY is proven to help maintain control of symptoms and IGF-1 levels for a range of people with acromegaly.

People who want 
to change medications

Ready for a change? PALSONIFY may help—even if injections weren’t right for you.

People who have discontinued medication

Previous medication didn’t work for you? PALSONIFY is different.

People new to treatment

Just diagnosed but not right for surgery? Or had surgery but still not fully controlled? Start with PALSONIFY.

IGF-1=insulin-like growth factor 1.

Designed to treat acromegaly all day

PALSONIFY is specifically made to be a once-daily oral treatment that’s absorbed efficiently through your digestive system—unlike injections. It’s designed to stay active in your body for over 24 hours, which helps maintain a steady level of medicine throughout the day with just one daily dose.

Powerful yet predictable, PALSONIFY is proven to:

Icon of two downward facing arrows.

Lower and maintain  IGF-1 levels*

Icon of a line graph with data points

Normalize IGF-1 in 2 to 4 weeks*

Icon of a smiling face with light rays, expressing happiness.

Reduce symptoms of acromegaly†

*In a 24-week study of 111 people with acromegaly who were new to medication or restarting after a break, 56% of those taking PALSONIFY reached normal IGF-1 levels compared with 5% taking placebo. The majority of people who achieved IGF-1 normalization did so within the first 2 to 4 weeks. In a 36-week study of 58 people switching from injections, 83% of those taking PALSONIFY maintained normal IGF-1 levels compared with 4% taking placebo.

†In both studies, people taking PALSONIFY experienced a reduction in the severity of common acromegaly symptoms.

The most common PALSONIFY side effects for people switching from injections were diarrhea (23%), nausea (13%), loss of appetite (10%), irregular heartbeat (palpitations) (7%), and stomach bug–like symptoms (gastroenteritis) (7%). The most common PALSONIFY side effects for people new to or restarting medication were diarrhea (33%), stomach pain or discomfort (19%), nausea (9%), slow heart rate (bradycardia) (7%), and high blood sugar (7%).

CrinetiCARE provides personalized support to help

Start PALSONIFY with support

CrinetiCARE provides personalized support to help you navigate your treatment journey with PALSONIFY.

Whether you have questions about insurance coverage, need help finding a healthcare provider, or are seeking a nurse educator, CrinetiCARE is here to help.

Get support